AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

Index of articles > Medicine and Health > Health publications > WHO Drug Information articles > January 2001 articles
Close

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-10234730_ITM" title="Facts and information about Rivastigmine: revised product information.">Rivastigmine: revised product information.</a>
Close Set up an RSS feed that alerts you when new articles from WHO Drug Information are available.
XML Add to My Yahoo! Add to My AOL Add to Google Subscribe in NewsGator
Frequently asked questions about RSS feeds

Rivastigmine: revised product information.

WHO Drug Information

| January 01, 2001 | COPYRIGHT 1999 World Health Organization. (Hide copyright information)Copyright

United States of America -- The manufacturer of rivastigmine (Exelon[R]), indicated for Alzheimer disease has informed health professionals of recent changes to the prescribing information. These changes provide guidelines for reinitiating therapy in patients who have interrupted treatment with rivastigmine in order to reduce the risk of severe vomiting. (1)

There is limited experience related to restarting rivastigmine after an interruption in therapy at doses higher than the recommended starting dose. However, to reduce the possibility of severe vomiting in patients who have interrupted therapy for longer than several days, treatment should be reinitiated with the …

View articles courtesy of your local library
Related articles from newspapers, magazines, journals, and more
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily